135 related articles for article (PubMed ID: 26811414)
1. Hyperphosphatemic tumoural calcinosis.
Shetty S; Kapoor N; Mathai S; Paul TV
BMJ Case Rep; 2016 Jan; 2016():. PubMed ID: 26811414
[No Abstract] [Full Text] [Related]
2. Recurrent hyperphosphatemic tumoural calcinosis.
Amit S; Agarwal A; Nigam A; Rao YK
BMJ Case Rep; 2012 Sep; 2012():. PubMed ID: 23010461
[TBL] [Abstract][Full Text] [Related]
3. Familial hyperphosphatemic tumoral calcinosis in an unusual and usual sites and dramatic improvement with the treatment of acetazolamide, sevelamer and topical sodium thiosulfate.
Emecen Sanli M; Kilic A; Aktasoglu E; Inci A; Okur I; Ezgu F; Tumer L
J Pediatr Endocrinol Metab; 2021 Jun; 34(6):813-816. PubMed ID: 33819418
[TBL] [Abstract][Full Text] [Related]
4. Hyperphosphatemic tumoral calcinosis caused by FGF23 compound heterozygous mutations: what are the therapeutic options for a better control of phosphatemia?
Claramunt-Taberner D; Bertholet-Thomas A; Carlier MC; Dijoud F; Chotel F; Silve C; Bacchetta J
Pediatr Nephrol; 2018 Jul; 33(7):1263-1267. PubMed ID: 29594503
[TBL] [Abstract][Full Text] [Related]
5. The Case | Subcutaneous abdominal calcified nodules and severe hyperphosphatemia.
Seront B; Marot L; Demoulin N; Jadoul M; Morelle J
Kidney Int; 2016 May; 89(5):1171-1172. PubMed ID: 27083299
[No Abstract] [Full Text] [Related]
6. Tumoral calcinosis with hyperphosphatemia.
Mahadevan S; Adhisivam B; Kumar CN
Indian J Pediatr; 2005 Oct; 72(10):889-90. PubMed ID: 16272668
[TBL] [Abstract][Full Text] [Related]
7. Hyperphosphatemic familial tumoral calcinosis: response to acetazolamide and postulated mechanisms.
Finer G; Price HE; Shore RM; White KE; Langman CB
Am J Med Genet A; 2014 Jun; 164A(6):1545-9. PubMed ID: 24668887
[TBL] [Abstract][Full Text] [Related]
8. Sevelamer Versus Calcium-Based Binders for Treatment of Hyperphosphatemia in CKD: A Meta-Analysis of Randomized Controlled Trials.
Patel L; Bernard LM; Elder GJ
Clin J Am Soc Nephrol; 2016 Feb; 11(2):232-44. PubMed ID: 26668024
[TBL] [Abstract][Full Text] [Related]
9. [Phosphate binders in chronic kidney disease: the positions of sevelamer].
Fomin VV; Shilov EM; Svistunov AA; Milovanov IuS
Ter Arkh; 2013; 85(6):96-9. PubMed ID: 23875200
[TBL] [Abstract][Full Text] [Related]
10. A rare disorder: tumoral calcinosis and cirrhosis.
Allameh SF; Anari AG; Gharabaghi MA; Nakhjavani M
BMJ Case Rep; 2011 Aug; 2011():. PubMed ID: 22688940
[TBL] [Abstract][Full Text] [Related]
11. Hyperostosis with hyperphosphatemia and tumoral calcinosis: a case report.
Otukesh H; Hoseini R; Chalian H; Chalian M; Safarzadeh AE; Shakiba M; Poorian A
Pediatr Nephrol; 2007 Aug; 22(8):1235-7. PubMed ID: 17437133
[TBL] [Abstract][Full Text] [Related]
12. [Treatment of hyperphosphatemia with sevelamer hydrochloride in CKD patients: effects on vascular calcification and mortality].
Koizumi M; Fukagawa M
Clin Calcium; 2010 Nov; 20(11):1700-8. PubMed ID: 21037391
[TBL] [Abstract][Full Text] [Related]
13. Sevelamer Hydrochloride for Tumor Lysis Syndrome-related Hyperphosphatemia.
Prasada H
Indian Pediatr; 2015 Jul; 52(7):613-5. PubMed ID: 26244958
[TBL] [Abstract][Full Text] [Related]
14. Beneficial Response to Phosphate Lowering Therapy in Normophosphatemic Tumoral Calcinosis.
Soumya S; Prasad N; Jabbar PK; Hussain S; Jayakumari C; Nair A
Indian Pediatr; 2021 Jan; 58(1):88-89. PubMed ID: 33452789
[No Abstract] [Full Text] [Related]
15. Phosphate binders, cardiovascular calcifications and mortality: do we need another survival study with sevelamer?
Negri AL
J Nephrol; 2010; 23(6):653-7. PubMed ID: 20349415
[TBL] [Abstract][Full Text] [Related]
16. Nonfamilial hyperphosphatemic tumoral calcinosis with ulnar neuropathy.
Shetty GM; Murari AS; Shah SV; Dhengle S
Joint Bone Spine; 2009 Mar; 76(2):198-201. PubMed ID: 19073370
[TBL] [Abstract][Full Text] [Related]
17. Hyperphosphatemia and phosphate binders: effectiveness and safety.
Kalaitzidis RG; Elisaf MS
Curr Med Res Opin; 2014 Jan; 30(1):109-12. PubMed ID: 24007207
[TBL] [Abstract][Full Text] [Related]
18. Randomized controlled trial of bixalomer versus sevelamer hydrochloride in hemodialysis patients with hyperphosphatemia.
Akizawa T; Origasa H; Kameoka C; Kaneko Y; Kawasaki S;
Ther Apher Dial; 2014 Apr; 18(2):122-31. PubMed ID: 24720402
[TBL] [Abstract][Full Text] [Related]
19. Sevelamer hydrochloride: a novel treatment of hyperphosphatemia associated with tumor lysis syndrome in children.
Abdullah S; Diezi M; Sung L; Dupuis LL; Geary D; Abla O
Pediatr Blood Cancer; 2008 Jul; 51(1):59-61. PubMed ID: 18240167
[TBL] [Abstract][Full Text] [Related]
20. Autoimmune hyperphosphatemic tumoral calcinosis in a patient with FGF23 autoantibodies.
Roberts MS; Burbelo PD; Egli-Spichtig D; Perwad F; Romero CJ; Ichikawa S; Farrow E; Econs MJ; Guthrie LC; Collins MT; Gafni RI
J Clin Invest; 2018 Dec; 128(12):5368-5373. PubMed ID: 30226830
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
